Defibrotide PharmaSwiss
Defibrotide PharmaSwiss Uses, Dosage, Side Effects, Food Interaction and all others data.
Defibrotide PharmaSwiss is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.
Defibrotide PharmaSwiss is a deoxyribonucleic acid derivative extracted from mammalian organs, which has been developed for the treatment of a number of vascular disorders. It appears to increase fibrinolysis and may possess antithrombotic, antiatherosclerotic and anti-ischaemic actions, probably due to its ability to selectively increase prostaglandin I2 and E2 levels and to increase tissue plasminogen activator and decrease plasminogen activator inhibitor function. Defibrotide PharmaSwiss is available as an intravenous and intramuscular preparation, and also as an oral formulation for long term use.
| Trade Name | Defibrotide PharmaSwiss |
| Availability | Prescription only |
| Generic | Defibrotide |
| Defibrotide Other Names | Defibrotide free acid, Defibrotide free acid (porcine mucosa), Defibrotide free acid (porcine) |
| Related Drugs | Defitelio |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Slovenia |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Defibrotide PharmaSwiss is a mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
Indicated for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
Defibrotide PharmaSwiss is also used to associated treatment for these conditions: Sinusoidal Obstruction Syndrome (SOS)
How Defibrotide PharmaSwiss works
The drug appears to prevent the formation of blood clots and to help dissolve blood clots by increasing levels of prostaglandin I2, E2, and prostacyclin, altering platelet activity, increasing tissue plasminogen activator function, and decreasing activity of tissue plasminogen activator inhibitor. Prostaglandin I2 relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other. Prostaglandin E2 at certain concentrations also inhibits platelet aggregation. Moreover, the drug provides additional beneficial anti-inflammatory and antiischemic activities as recent sudies have shown. It is yet unclear, if the latter effects can be utilized clinically (e.g., treatment of ischemic stroke).
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Defibrotide PharmaSwiss Drug Interaction
Unknown: charcoal, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, glucose, diltiazem, glycerin, sodium iodide, arginine, levocarnitine, cysteine, lithium, metoprolol, metoprolol, acetaminophen, bioflavonoids, valproic acid, thiamine, cyanocobalamin, pyridoxine
Defibrotide PharmaSwiss Disease Interaction
Elimination Route
Bioavailability is 58-70% following oral administration, compared to parenteral forms (i.v. and i.m. = 100%).
Half Life
t1/2-alpha = minutes (10-20 minutes in rat); t1/2-beta = a few hours
Innovators Monograph
You find simplified version here Defibrotide PharmaSwiss
